Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition t
Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant.
India's Sun Pharmaceutical has signed an agreement to acquire US biotech Concert Pharmaceuticals and its lead drug deuroxilitinib, in phase 3 testing for alopecia areata, a leading cause of
Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh